Compliance and Enforcement Warning letter to Hims & Hers cites implied claims On September 9, the FDA sent Hims & Hers a Warning Letter calling out advertisements for compounded semaglutide that imply that your products are the same as an FDA-approved product when they are not, since compounded drug products are not FDA-approved
The only treatment that has consistently demonstrated long-term success in managing obesity is metabolic surgery, says Tyler Cohn, MD, interim director, division of minimally invasive, bariatric and community general surgery at Loyola Medicine
Edmunds recommends taking semaglutide in the evening so you can sleep through some of the nausea, and avoiding high-fat foods in the days surrounding your injection
GLP-1 (glucagon-like peptide-1) receptor agonists are injectable medications that: Slow digestion to reduce appetite Stimulate insulin production to lower blood sugar Promote weight loss (up to 15% of body weight in some cases) Common brands include: Ozempic (semaglutide) for type 2 diabetes Wegovy (semaglutide) for obesity Mounjaro (tirzepatide) for diabetes and weight loss According to the American Diabetes Association, over 8 million Americans now use GLP-1 drugs-and their foot health impacts are significant
Drug access, food and nutrition insecurity, and nutrition and culinary knowledge influence equitable obesity management with GLP-1s [71]
